Rosuvastatin and atorvastatin differ mainly in intensity of action, metabolic pathway, adverse effects, etc.
1. Intensity of action: at the same dose, the lipid-lowering effect of Rosuvastatin calcium is stronger than that of Atorvastatin.
2. Metabolic pathway: Atorvastatin is mainly metabolized by the liver, while Rosuvastatin is metabolized by the liver and kidney.
3. Adverse effects: The adverse effects of atorvastatin include liver function injury such as elevated ghrelin, muscle injury such as myalgia, muscle weakness, etc. The adverse effects of Rosuvastatin also include abdominal distension, loss of appetite, muscle weakness, rhabdomyolysis, etc. In general, atorvastatin is associated with liver function impairment, muscle weakness, muscle lysis, etc. The adverse effects of atorvastatin are mainly metabolized by the liver. Generally the hepatotoxicity of atorvastatin is higher, while the nephrotoxicity and muscular toxicity of Rosuvastatin are higher.
Atorvastatin is mainly contraindicated in patients with active liver disease, as well as in pregnant and breastfeeding women and in those who are allergic to the drug. Rosuvastatin is contraindicated in patients with active liver disease and myopathy, in pregnant women, and in those who are allergic to the drug.
Both are statin lipid-lowering drugs and are indicated for patients with different medical conditions. It is recommended to consult a specialist for the use of statins under the supervision of a physician.